Tysabri Webcast Citation May Signal That FDA Could Treat All Social Media Interactions As Promotional; Biogen's PML Strategy Also Takes A Hit
FDA appears to be gearing up to treat social media interactions as promotional even when they are aimed solely at informing physicians
You may also be interested in...
Advertising Regulation Wiki? Industry Wants Authoritative But Frequently Updated FDA Guidance (And/Or Regs) On Internet Drug Promotion
It's up to FDA now to outline a "how-to" for drug makers when it comes to using the Internet and social media for drug promotion - with guidance, regulations or both. But drug makers made evident in comments on the agency's meeting last fall that FDA also must determine how to account for changing technologies
Biogen Idec's decision to start providing doctors with monthly updates on progressive multifocal leukoencephalopathy cases among Tysabri patients shows the firm's confidence that providing additional risk information will not discourage use of the product
Compensation and collaboration - as well as creation - should be the triggers for determining a pharmaceutical company's liability for Internet content, Rohit Bhargava of Ogilvy 360 Digital Influence advised FDA during a Nov. 12-13 hearing on promoting medical products on the Internet and in social media